Skip to main content
Anteris Technologies Global Corp. logo

Anteris Technologies Global Corp. — Investor Relations & Filings

Ticker · AVR ISIN · US03675P1021 ASX Manufacturing
Open in API
Filings indexed 1,667 across all filing types
Latest filing 2008-04-30 Regulatory Filings
Country US United States of America
Listing ASX AVR

About Anteris Technologies Global Corp.

https://anteristech.com/

Anteris Technologies is a structural heart company focused on the development and commercialization of medical devices for heart valve disease. Its lead product is the DurAVR® Transcatheter Heart Valve (THV), a biomimetic valve designed for patients with severe aortic stenosis. The DurAVR® THV is engineered to mimic the performance of a healthy human aortic valve, aiming to restore normal, laminar blood flow. Clinical studies have shown the device delivers a favorable hemodynamic profile, characterized by low pressure gradients and a significant reduction in prosthesis-patient mismatch (PPM), even in patients with challenging anatomies. The company is advancing its technology through pivotal clinical trials to establish a new standard in transcatheter aortic valve replacement (TAVR) and improve long-term patient outcomes.

Recent filings

Filing Released Lang Actions
First human implant of cardiocel adapt biomaterial patches 3 pages ?Kb
Regulatory Filings Classification · 95% confidence The document is an ASX announcement dated 1 May 2008 from bioMD Limited regarding the first human implant of their CardioCel biomaterial patches. It describes the clinical trial details, product development status, trial locations, patient selection, and follow-up procedures. The content is an announcement of a clinical milestone and trial initiation rather than a financial report, earnings release, or regulatory filing. It does not contain financial statements, management discussion, or voting results. The document is relatively short (6287 characters) and serves as a news update about a clinical trial and product development progress. Therefore, it fits best under the category of a Regulatory Filing (RNS) as a general regulatory announcement that does not fit other specific categories.
2008-04-30 English
Presentation Excellence in Biotechnology Investment conferen 14 pages ?Kb
Regulatory Filings
2008-04-20 English
Appendix 4C - quarterly 7 pages ?Kb
Interim / Quarterly Report Classification · 100% confidence The document is titled as a 'Quarterly Report' and references 'Appendix 4C - Quarterly Report' for the period ended 31 March 2008. It contains detailed financial data including consolidated cash flow statements, cash reconciliation, and financing activities for the quarter and year to date. It also includes operational highlights, research and development updates, and regulatory information. The length of the document (over 10,000 characters) and the presence of substantive financial data and analysis confirm it is a full quarterly report rather than a brief announcement or certification. Therefore, the document fits the definition of an Interim / Quarterly Report (IR). Q3 2008
2008-04-10 English
Research coverage 1 page ?Kb
Regulatory Filings Classification · 95% confidence The document is an ASX announcement dated 4 April 2008, titled 'RESEARCH COVERAGE'. It directs shareholders and the market to the company's website for initial research coverage by Bioshares. The content is brief, promotional, and does not contain any financial data, detailed report, or regulatory filing. It is essentially an announcement about research coverage availability rather than a financial report or detailed investor presentation. Given the short length (1291 characters) and the nature of the content, it does not qualify as an Annual Report, Interim Report, Earnings Release, or Investor Presentation. It is not a regulatory filing or certification either. The best fitting category is Regulatory Filings (RNS) as a general announcement that does not fit other categories.
2008-04-03 English
Change of Director`s Interest Notice 2 pages ?Kb
Director's Dealing Classification · 100% confidence The document is an announcement to the Australian Stock Exchange regarding a change in a director's interest in securities, specifically an Appendix 3Y form. It details the director's shareholdings before and after the change, the nature of the change, and references compliance with listing rules and the Corporations Act. This matches the definition of a Director's Dealing report, which involves reporting personal share transactions by company directors and executives. The document is short and focused solely on this transaction, with no financial statements or broader company information. Therefore, the appropriate classification is Director's Dealing (DIRS).
2008-03-31 English
Change in substantial holding 3 pages ?Kb
Major Shareholding Notification Classification · 100% confidence The document is titled 'Change of Substantial Holder Notice' and includes a Form 604 under the Corporations Act 2001 Section 671B, which is a formal notice of change in interests of a substantial shareholder. It details changes in voting power and shareholdings of Mandolin Pty Ltd in bioMD Limited. The document is an official notification of changes in significant share ownership levels, not a financial report, earnings release, or management information. Therefore, it fits the category of Major Shareholding Notification (MRQ). The document length is 7747 characters, which is sufficient for a detailed notice rather than a brief announcement or certification. Hence, the classification is MRQ with high confidence.
2008-03-31 English

Browse filings by year

23 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.